Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 12/20 | 1.00 |
| ▸ | CNR1 | P21554 | 10/20 | 0.56 |
| ▸ | PNLIP | P16233 | 3/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | DAGLB | Q8NCG7 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.50 |
| ▸ | LPL | P06858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LIPC | P11150 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | FASN | P49327 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.50 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9456849 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL4132200 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL12083542 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL715603 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL8780224 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL9262903 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL12083717 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL9456844 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL21055846 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 | |
| SCHEMBL715602 | 1.00 | DAGLA (1.00) | DAGLACNR1PNLIPMGLLCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118593478-A | Application of orlistat and gemcitabine in preparation of pancreatic cancer treatment drugs | 中国药科大学 | 2024-09-06 | — | — | CN | claimed |
| CN-109851592-B | Orlistat derivatives | 中国人民解放军西部战区总医院 | 2023-04-11 | — | — | CN | claimed |
| US-5175186-A | Inhibits pancreas lepase and useful agent in treatment of obesity, hyperlipemia, atherosclerosis and arteriosclerosis | HOFFMANN-LA ROCHE INC. (US) | 1992-12-29 | — | — | US | claimed |
| CN-118593478-A | Application of orlistat and gemcitabine in preparation of pancreatic cancer treatment drugs | 中国药科大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-109851592-B | Orlistat derivatives | 中国人民解放军西部战区总医院 | 2023-04-11 | — | — | CN | disclosed |
| CN-111004272-B | Preparation method of orlistat chiral intermediate | 佛山奕安赛医药科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-2280007-B1 | THE PREPARATION METHOD OF (3S,4S)-3-HEXYL-4-((R)-2-HYDROXYTRIDECYL)-OXETAN-2-ONE AND THE PRODUCT OF THAT METHOD | CHONGQING ZHIEN PHARMACEUTICAL CO LTD (CN) | 2015-04-29 | — | — | EP | disclosed |
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | NIH - DEITR | 2015-04-09 | — | — | US | disclosed |
| EP-2376469-B1 | METHOD FOR PREPARING (3S,4S)-4-((R)-2-(BENZYLOXY)TRIDECYL)-3-HEXYL-2-OXETANONE AND NOVEL INTERMEDIATE USED THEREFOR | HANMI SCIENCE CO LTD (KR) | 2014-04-30 | — | — | EP | disclosed |
| US-8637700-B2 | Method for preparing (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used therefor | HANMI SCIENCE CO., LTD (KR) | 2014-01-28 | — | — | US | disclosed |
| CN-101939308-B | Preparation method of (3s,4s)-3-hexyl-4-((R)-2-hydroxytridecyl)-oxetan-2-one and product of that method | CHONGQING ZHIEN PHARMACEUTICAL CO LTD | 2013-10-23 | — | — | CN | disclosed |
| US-5246960-A | Used to treat obesity, hyperlipaemia, atherosclerosis and arteriosclerosis | HOFFMANN-LA ROCHE INC. (US) | 1993-09-21 | — | — | US | disclosed |
| US-5245056-A | PRODUCTION OF OXETANONES | HOFFMANN-LA ROCHE INC. (US) | 1993-09-14 | — | — | US | disclosed |
| US-5175186-A | Inhibits pancreas lepase and useful agent in treatment of obesity, hyperlipemia, atherosclerosis and arteriosclerosis | HOFFMANN-LA ROCHE INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0444482-A2 | Oxetanones | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-04 | — | — | EP | disclosed |
| US-4983746-A | Oxetanones and process for their production | HOFFMANN-LA ROCHE INC. (US) | 1991-01-08 | — | — | US | disclosed |
| US-4931463-A | PANCREAS LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0189577-B1 | PROCESS FOR THE PREPARATION OF OXETANONES | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-13 | — | — | EP | disclosed |
| EP-0189577-A2 | Process for the preparation of oxetanones | F. HOFFMANN-LA ROCHE AG (CH) | 1986-08-06 | — | — | EP | disclosed |
| EP-0185359-A2 | Oxetanone | F. HOFFMANN-LA ROCHE AG (CH) | 1986-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | PNLIP, LIPE, LIPC | DAGLA 8/4885CNR1 941/4885PNLIP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.